Meeting Overview | We are pleased to invite you to our satellite symposium, titled Optimizing Outcomes Across the Spectrum of Myeloproliferative Neoplasms, to be held on 9 June 2011 at the 16th Congress of the European Hematology Association in London, United Kingdom. |
Date and Location | 9 June 2011
Hall S1
ExCel London
One Western Gateway
Royal Victoria Dock, London E16 1XL
United Kingdom
|
Target Audience | This educational activity is designed for hematologists, oncologists, and other healthcare providers actively involved in the management of patients with myeloproliferative disorders. |
 Learning Objectives | Upon completion of this educational activity, participants should be able to:
- Evaluate the efficacy and safety of front-line treatment options for chronic myelogenous leukemia, and explain how to integrate optimal treatments into clinical practice
- Discuss emerging second-line treatment options for chronic myelogenous leukemia, and assess the impact of results from recent clinical trials on clinical practice
- Describe current diagnostic criteria and risk-stratification methods for the Philadelphia chromosome–negative myeloproliferative neoplasms and the implementation of these strategies into clinical practice
- Evaluate recent clinical trial data regarding therapeutic advances in the management of patients with Philadelphia chromosome–negative myeloproliferative neoplasms, and assess the practical implications of these data
|
Faculty | Co-Chairs
Michele Baccarani, MD
University of Bologna
Bologna, Italy
|
Srdan Verstovsek, MD, PhD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas, United States
|
Faculty
Francisco Cervantes, MD, PhD
Hospital Clinic Barcelona
Barcelona, Spain
|
Guido Finazzi, MD
Ospedali Riuniti
Bergamo, Italy
|
|
Agenda |
| 13.30 |
|
Welcome and introduction
|
| 13.35 |
|
Interactive clinical opinion poll
|
| 13.40 |
|
Challenges to the standard of care for patients with
newly diagnosed CML
Michele Baccarani, MD
|
| 14.00 |
|
Interactive clinical opinion poll
|
| 14.05 |
|
Second-line CML: Which agent and when?
Francisco Cervantes, MD, PhD
|
| 14.25 |
|
Interactive clinical opinion poll
|
| 14.30 |
|
Evolving paradigms in the diagnosis and prognosis
of myeloproliferative neoplasm
Guido Finazzi, MD
|
| 14.50 |
|
Interactive clinical opinion poll
|
| 14.55 |
|
Myeloproliferative neoplasms: Current and emerging therapies
Srdan Verstovsek, MD, PhD
|
| 15.15 |
|
Expert commentary
All Faculty
|
| 15.30 |
|
Adjourn
|
|
|
|
|
Continuing Professional Development | This activity has been approved for 2 External credits by the Federation of the Royal College of Physicians (UK). Delegates are reminded that a maximum of six External CPD points may be counted for educational activity on any one day. RCP Activity Code #: 64454. |
Support | Support for this activity has been provided by ARIAD Pharmaceuticals and Novartis Oncology.
 |
ORGANIZER | This meeting is a prIME Oncology activity.
 |
|
